转录组
CD8型
无容量
T细胞受体
生物
免疫检查点
免疫系统
基因签名
T细胞
癌症研究
细胞毒性T细胞
细胞
免疫疗法
计算生物学
基因
免疫学
基因表达
遗传学
体外
作者
Namit Kumar,Simon Papillon‐Cavanagh,Hao Tang,Shiliang Wang,Caitlyn Stromko,Ching‐Ping Ho,Sonal Soni‐Sheth,Steven G. Grinnell,Miranda L. Broz,Daniel J. Tenney,Michael J. Wichroski,Alice M. Walsh,Yanhua Hu,Joseph L. Benci
摘要
Abstract Immune checkpoint blockade (ICB) has led to durable clinical responses in multiple cancer types. However, biomarkers that identify which patients are most likely to respond to ICB are not well defined. Many putative biomarkers developed from a small number of samples often fail to maintain their predictive status in larger validation cohorts. We show across multiple human malignancies and syngeneic murine tumor models that neither pretreatment T cell receptor (TCR) clonality nor changes in clonality after ICB correlate with response. Dissection of tumor infiltrating lymphocytes pre‐ and post‐ICB by paired single‐cell RNA sequencing and single‐cell TCR sequencing reveals conserved and distinct transcriptomic features in expanded TCR clonotypes between anti‐PD1 responder and nonresponder murine tumor models. Overall, our results indicate a productive anti‐tumor response is agnostic of TCR clonal expansion. Further, we used single‐cell transcriptomics to develop a CD8+ T cell specific gene signature for a productive anti‐tumor response and show the response signature to be associated with overall survival (OS) on nivolumab monotherapy in CheckMate‐067, a phase 3 clinical trial in metastatic melanoma. These results highlight the value of leveraging single‐cell assays to dissect heterogeneous tumor and immune subsets and define cell‐type specific transcriptomic biomarkers of ICB response.
科研通智能强力驱动
Strongly Powered by AbleSci AI